119 related articles for article (PubMed ID: 21830159)
1. Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.
Yakabe T; Noshiro H; Ikeda O; Miyoshi A; Kitajima Y; Satoh S
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1499-504. PubMed ID: 21830159
[TBL] [Abstract][Full Text] [Related]
2. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
[TBL] [Abstract][Full Text] [Related]
3. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
[TBL] [Abstract][Full Text] [Related]
5. [Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer].
Kitajima Y; Yakabe T; Ohtsuka T; Tanaka M; Sato S; Nakafusa Y; Miyazaki K
Gan To Kagaku Ryoho; 2009 May; 36(5):851-4. PubMed ID: 19461193
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer.
Takeyoshi I; Makita F; Tanahashi Y; Iwazaki S; Ogawa T; Tomizawa N; Nakamura S; Ishikawa H; Ohya T; Kakinuma S; Nakagami K; Sato Y; Koyano T; Roppongi T; Izumi M; Kobayashi J; Kawate S; Sunose Y; Kobayashi M; Yamada T; Sakamoto I
Anticancer Res; 2011 Jan; 31(1):287-91. PubMed ID: 21273612
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer.
Ohashi M; Kanda T; Kobayashi T; Hirota M; Hayami M; Yajima K; Matsuki A; Kosugi S; Hatakeyama K;
Hepatogastroenterology; 2011; 58(106):652-8. PubMed ID: 21674889
[TBL] [Abstract][Full Text] [Related]
9. Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.
Yoshino S; Furuya T; Shimizu R; Ozasa H; Nishimura T; Fukuda S; Kawaoka T; Hazama S; Oka M
Anticancer Res; 2013 Jun; 33(6):2629-33. PubMed ID: 23749919
[TBL] [Abstract][Full Text] [Related]
10. [A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice].
Matsuyama J; Naitou A; Hiraki M; Matsumoto S; Hashimoto K; Yokoyama S; Morita S; Morimoto T; Fukushima Y; Nishishou I; Nomura T; Sasaki Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2297-9. PubMed ID: 20037401
[TBL] [Abstract][Full Text] [Related]
11. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
[TBL] [Abstract][Full Text] [Related]
12. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Nakanishi K; Kobayashi D; Mochizuki Y; Ishigure K; Ito S; Kojima H; Ishiyama A; Fujitake S; Shikano T; Morita S; Kodera Y
Int J Clin Oncol; 2016 Jun; 21(3):557-65. PubMed ID: 26547424
[TBL] [Abstract][Full Text] [Related]
13. [A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
Kuwakado S; Takiuchi H; Goto M; Kawabe S; Ohta S; Kii T; Tanaka T; Nishitani H; Katsu K
Gan To Kagaku Ryoho; 2006 Apr; 33(4):513-5. PubMed ID: 16612164
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients.
Yeh YS; Tsai HL; Ma CJ; Wu DC; Lu CY; Wu IC; Hou MF; Wang JY
Chemotherapy; 2012; 58(5):411-8. PubMed ID: 23306825
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
17. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
18. [A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment].
Oneyama M; Sekikawa K; Goto M; Kitamura M; Kawahara Y; Ohta R; Takahashi Y; Hirata Y; Nakayama M; Shimoda Y
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1131-3. PubMed ID: 22790054
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Okamoto K; Otsuji E; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Yamashita T; Taniguchi F; Aragane H; Nishi H; Itokawa Y; Morita S; Sakamoto J
Gastric Cancer; 2010 Aug; 13(3):149-54. PubMed ID: 20820983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
